PIIND2026-04-012026-06-30PIIND2026-06-30PIIND2026-04-012026-06-30in-capmkt:OtherExpenses1MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses2MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses3MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses4MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses5MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses6MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses7MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses8MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses9MemberPIIND2026-04-012026-06-30in-capmkt:OtherExpenses10MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments1MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments2MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments3MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments1MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments2MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments3MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments1MemberPIIND2026-06-30in-capmkt:ReportableSegments1MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments2MemberPIIND2026-06-30in-capmkt:ReportableSegments2MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments3MemberPIIND2026-06-30in-capmkt:ReportableSegments3MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments1MemberPIIND2026-06-30in-capmkt:ReportableSegments1MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments2MemberPIIND2026-06-30in-capmkt:ReportableSegments2MemberPIIND2026-04-012026-06-30in-capmkt:ReportableSegments3MemberPIIND2026-06-30in-capmkt:ReportableSegments3MemberPIIND2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1PIIND2026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1PIIND2026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares523642PIINDNOTLISTEDINE603J01030PI INDUSTRIES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-112026-08-03INRMillionsQuarterlyFirst quarterMulti segment2026-08-1114:00:002026-08-1118:30:00Not applicable2026-04-012026-06-30UnauditedConsolidated1702300000064100000017664000000681900000042300000012300000026080000007900000010370000003376000000144650000003199000000031990000007300000004600000077600000002423000000000190000002442000000320000000276200000027620000000152000000116.116.10016.116.11 The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on August 11, 2026. <br /> <br /> 2 The Consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. <br /> <br /> 3 The Consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) PI AgSciencies, S. de R.L. de C.V. (Formerly known as Plant Health Care de Mexico S. de R.L. de C.V.) (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care España) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ;Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited ; Associate - Solinnos Agro Sciences Private Limited. <br /> <br /> 4 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures for the nine month period ended December 31, 2025. <br /> <br /> 5 a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. <br /> <br /> Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement resulted in a write-back of the contingent consideration of Rs. 1,260 Mn, which was presented under Exceptional Items during the year ended March 31, 2026. <br /> <br /> b) Pursuant to the notification of the New Labour Codes as issued in November 2025, the Group reassessed its employee benefit obligations in accordance with the revised definition of wages and accordingly, an incremental liability of Rs. 229 Mn had been disclosed as an Exceptional Item during the year ended March 31, 2026. <br /> 6 Segment information as per Ind AS 108 Operating Segments is as per Annexure I. <br /> Net impairment losses on financial assets52000000Power, Fuel & Water799000000Environment & Pollution Control Expenses266000000Freight & Cartage146000000Advertisement & Sales Promotion236000000Travelling and Conveyance313000000Legal & professional fees287000000Repairs & Maintenance356000000Laboratory & Testing Charges157000000Other expenses764000000Agro Chemicals16488000000Pharma542000000Inter Segment adjustment017030000000700000017023000000Agro Chemicals3835000000Pharma-816000000Inter Segment adjustment1990000003218000000003218000000Agro Chemicals124549000000Pharma14561000000Inter Segment adjustment01391100000000139110000000Agro Chemicals20696000000Pharma3731000000Inter Segment adjustment024427000000024427000000Note: The business of the group is divided into two segments as below: <br /> a) Agro chemicals - Agro chemicals includes Agchem export (CSM), Domestic Agri Brands and Biologicals. <br /> b) Pharma - Pharma comprises contract research and development, contract development and manufacturing of active, key starting materials and intermediates used in pharmaceutical industry.Remeasurements gain/(loss) on defined benefits plans900000090000005000000Effective portion of gain/(loss) on cash flow hedges571000000Exchange difference on translation of foreign operations-55000000516000000200000000320000000